- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07467447
Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight (GZBF)
Een fase 2-studie van eenmaal per week LY3437943 vergeleken met placebo bij deelnemers met obesitas of overgewicht met gewichtsgerelateerde comorbiditeiten
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
After screening (up to 6 weeks), eligible participants are randomized to one of several dose-escalation regimens leading to maintenance doses of 1, 4, 8, or 12 mg retatrutide (or placebo) administered once weekly for 48 weeks, followed by a 4-week safety follow-up. Two maintenance dose levels (4 mg and 8 mg) include alternative escalation schedules to evaluate tolerability. The primary efficacy evaluation is at Week 24 (percent change in body weight), with additional weight, anthropometric, and safety assessments through Week 48.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Seni S Lu, Phd
- Telefoonnummer: +86 13076790030
- E-mail: Seni-Lu@beijing-biotech.com
Studie Locaties
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518036
- Werving
- Peking University Shenzhen Hospital
-
Contact:
- Zhen J Peng, Phd
- Telefoonnummer: +8613076790039
- E-mail: Zhen-Peng@beijing-biotech.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 to 75 years (inclusive) at time of informed consent.
- BMI ≥30 and ≤50 kg/m², OR BMI ≥27 and <30 kg/m² with at least 1 weight-related comorbidity (hypertension; dyslipidemia; or cardiovascular disease such as ischemic CVD or NYHA Class I-II heart failure).
- Motivated and able/willing to self-inject (or have trained assistance if needed) and follow study procedures, including lifestyle advice and questionnaires.
- Subgroup (NAFLD addendum): liver fat content ≥10% by MRI-PDFF (for participants invited to the addendum).
- Male and/or female; contraception requirements apply; women of childbearing potential must have negative pregnancy tests at specified visits and should not be breastfeeding.
- Capable of giving signed informed consent and complying with protocol requirements.
Exclusion Criteria:
- History of diabetes mellitus (type 1 or type 2), ketoacidosis, or hyperosmolar state/coma.
- Screening lab values suggestive of diabetes (HbA1c ≥6.5%; fasting glucose ≥126 mg/dL; or random glucose ≥200 mg/dL).
- Self-reported change in body weight >5 kg within 3 months prior to screening.
- Prior or planned surgical treatment for obesity (exceptions: liposuction/abdominoplasty >1 year prior).
- Current/planned endoscopic or device-based obesity therapy, or device removal within last 6 months (e.g., intragastric balloon, gastric artery embolization).
- Renal impairment: eGFR <45 mL/min/1.73 m² (CKD-EPI) at screening.
- Clinically significant gastric emptying abnormality (e.g., severe gastroparesis) or chronic drugs affecting GI motility.
- History of acute or chronic pancreatitis (exception for resolved gallstone pancreatitis post-cholecystectomy).
- TSH outside 0.4 to 6.0 mIU/L at screening (with protocol-defined exceptions).
- Obesity due to other endocrine disorders (e.g., Cushing's) or monogenic/syndromic obesity (e.g., Prader-Willi).
- Psychiatric exclusion criteria including unstable major depressive disorder/severe psychiatric disorder within 2 years; lifetime suicide attempt; PHQ-9 score ≥15; or specified Columbia-Suicide Severity Rating Scale (C-SSRS) findings within past month.
- Uncontrolled hypertension (systolic ≥160 mmHg and/or diastolic ≥100 mmHg) or elevated resting pulse rate (>100 bpm) at baseline.
- Recent (within 3 months) major cardiovascular events (e.g., MI, stroke, unstable angina, CHF hospitalization); tachyarrhythmia syndromes; NYHA Class III-IV CHF; or ECG abnormalities interfering with interpretation.
- Acute/chronic hepatitis or liver disease other than NAFLD; or screening labs: ALT >3× ULN, ALP >1.5× ULN, or total bilirubin >1.5× ULN (with exception).
- Elevated calcitonin at Visit 1 per protocol thresholds; personal/family history of medullary thyroid carcinoma or MEN2.
- Active/untreated malignancy or remission <5 years (with protocol exceptions for certain in-situ/skin cancers).
- Contraindication to GLP-1 receptor agonists, or other conditions that could prevent protocol compliance (including drug/alcohol abuse or eating disorder), per investigator judgment.
- Alcohol consumption >14 units/week (women) or >21 units/week (men).
- Recent marijuana/THC-containing product use within 3 months or unwillingness to abstain during trial (protocol exception for cannabidiol oil if agrees to refrain).
- Organ transplant history (except corneal transplant) or awaiting transplant.
- Hematologic conditions interfering with HbA1c measurement; recent large blood donation/transfusion/severe blood loss; hemoglobin below protocol thresholds.
- Severe atopy/multiple severe allergies or severe hypersensitivity reactions.
- Fasting triglycerides >500 mg/dL at screening (with stability requirement for lipid-lowering therapy).
- Significant active, uncontrolled medical condition or history posing risk or interfering with data interpretation, per investigator judgment.
- History of symptomatic gallbladder disease within past 2 years (protocol-defined exceptions after cholecystectomy).
- History of documented HIV infection.
- Chronic systemic glucocorticoid therapy within 3 months or active autoimmune abnormality likely to require systemic steroids during study (with specified formulation exceptions).
- Recent medications that may cause significant weight gain (e.g., tricyclic antidepressants, atypical antipsychotics, mood stabilizers) within 3 months.
- Recent use (within 3 months) of medications or remedies intended to promote weight loss (examples listed in protocol, including GLP-1 RAs).
- Use of metformin or other glucose-lowering medications (e.g., for PCOS or diabetes prevention) not permitted at entry.
- Started implantable/injectable contraceptives within 18 months prior to screening (IUDs allowed if used ≥3 months).
- Known allergies to GLP-1 receptor agonists or LY3437943.
- Currently enrolled in another investigational study or recent participation/treatment within 30 days (or 5 half-lives, whichever longer).
- Previously received LY3437943 in this or another study.
- Investigator site personnel directly affiliated with the study and/or their immediate family; or Lilly employees.
- Note: The publicly posted protocol references additional exclusion criteria numbered 52-57 in a separate protocol addendum (not included in the posted protocol PDF).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Retatrutide (LY3437943) 1 mg eenmaal per week (geen escalatie)
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
Experimenteel: Retatrutide 4 mg eenmaal per week, escalatiesubgroep (a): 2 mg → 4 mg.
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
Experimenteel: Retatrutide 4 mg eenmaal per week, subgroep (b): start 4 mg (geen escalatie).
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
Experimenteel: Retatrutide 8 mg eenmaal per week, subgroep (a): 2 mg → 4 mg → 8 mg
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
Experimenteel: Retatrutide 12 mg eenmaal per week: 2 mg → 4 mg → 8 mg → 12 mg.
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
Experimenteel: Placebo eenmaal per week (gematcht escalatieschema om de blindering te handhaven).
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
Experimenteel: Retatrutide 8 mg eenmaal per week, subgroep (b): 4 mg → 8 mg.
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Gemiddelde procentuele verandering in lichaamsgewicht vanaf randomisatie/baseline tot week 24.
Tijdsspanne: 24 weken
|
24 weken
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Gemiddeld procentuele verandering in lichaamsgewicht van baseline tot week 48
Tijdsspanne: 48 weken
|
48 weken
|
|
Aandeel deelnemers dat een gewichtsverlies van ≥5%, ≥10% en ≥15% bereikt na 24 en 48 weken.
Tijdsspanne: 48 weken
|
48 weken
|
|
Gemiddelde verandering in lichaamsgewicht (kg) na 24 en 48 weken.
Tijdsspanne: 48 weken
|
48 weken
|
|
Gemiddelde verandering in BMI (kg/m²) na 24 en 48 weken.
Tijdsspanne: 48 weken
|
48 weken
|
|
Gemiddelde verandering in tailleomtrek (cm) na 24 en 48 weken
Tijdsspanne: 48 weken
|
48 weken
|
|
Veiligheids- en verdraagbaarheidsresultaten (bijv., behandeling-gerelateerde bijwerkingen; ernstige bijwerkingen; afbrekingen als gevolg van bijwerkingen).
Tijdsspanne: 48 weken
|
48 weken
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- J1I-MC-GZBS
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .